Inactivation of the P16 (INK4A)/retinoblastoma (RB) or TP53 biochemical pathway is frequent event in most human cancers. Recent evidence has shown that P14ARF binds to MDM2 leading to an increased availability of wild type TP53 protein. Functional studies also support a putative tumor suppressor gene function for p14 ARF suggesting that p14 ARF or p53 inactivation may be functionally equivalent in tumorigenesis. To study the relative contribution of each pathway in tumorigenesis, we analysed and compared alterations of the p16, p14 ARF and p53 genes in 38 primary non-small cell lung cancers (NSCLCs) (19 adenocarcinomas and 19 squamous carcinoma). The p16 tumor suppressor gene was inactivated in 22 of 38 (58%) tumors. Twelve of these samples (31%) had homozygous deletions by microsatellite analysis; eight of them (21%) had p16 promoter hypermethylation detected by Methylation Speci®c PCR (MSP) and the remaining two (5%) harbored a point mutation in exon 2 by sequence analysis. The absence of P16 protein in every case was con®rmed by immunohistochemistry. Fourteen of the 22 tumors with p16 inactivation also inactivated the p14 ARF gene (12 with homozygous deletions extending into INK4a/ARF and two with exon 2 mutations). Mutations of p53 were found in 18 (47%) of the tumors and nine of them (50%) harbored p14 ARF inactivation. Thus, an inverse correlation was not found between p14 ARF and p53 genetic alterations (P=0.18; Fisher Exact Test). Our data con®rm that the p16 gene is frequently inactivated in NSCLC. Assuming that 9p deletion occurs ®rst, the common occurrence of p53 and p14
Introduction
One third of cancer deaths in the United States result from lung cancer. Recent advances in molecular biology have begun to reveal the underlying genetic targets of various mutagenic agents such as tobacco (Kratzke et al., 1992) . The genesis of non-small cell lung cancer (NSCLC) is the result of multiple acquired genetic events including mutations in oncogenes (e.g. K-ras) and tumor suppressor genes (e.g. p53, p16 and Rb) (Mitsudomi and Takahashi, 1996) . Recently, the p14 ARF gene, located at the same locus as p16 (CDKN2/MTS1/INK4A), has emerged as a new putative tumor suppressor gene. The P14ARF and P16 proteins are encoded by two dierent reading frames of the INK4a gene, that initiate in dierent ®rst exons and continue in alternative reading frames though a common exon 2 Stone et al., 1995) . Although encoded by the same locus both proteins seem to act in dierent cell cycle inhibition pathways. P16 protein belongs to a family of cyclin dependent kinases (CDKs) which inhibit the activities of CDK4 or 6/cyclin D and CDK2/cyclin E complexes. The inhibition results in the blockade of retinoblastoma protein (RB) phosphorylation leading to continued E2F sequestration and as a consequence, growth suppression (Chin et al., 1998) . Recent evidence suggests that P14ARF protein blocks MDM2 inhibition of TP53, resulting in an increase of TP53 levels which activate p21 transcription leading to cell cycle arrest (Chin et al., 1998) .
Collaboration between the Rb and p53 pathways in tumor suppression is evident from the observation that many tumor types exhibit p53 and Rb concomitant mutations (Markl and Jones, 1998 genotype alone (Ko and Prives, 1996) . Because P14ARF acts in the TP53 pathway it has been suggested that concomitant p14 ARF and p53 gene inactivation must be a rare event in the same tumor. Interestingly, in bladder carcinoma this inverse correlation seemed to hold true, except for a few restricted p53 mutations (in exons 2 ± 4) observed together with p14 ARF inactivation (Markl and Jones, 1998) . On the other hand, a recent report hinted at an absence of an inverse correlation between P14ARF expression and TP53 overexpression (indicative of point mutation) in lung cancer (Gazzeri et al., 1998) .
In the present study we analysed the frequency of p16, p53 and p14 ARF gene inactivation in 38 primary NSCLCs. Our goal was to compare the frequency and patterns of p53 mutations in relation to p16 and p14 alterations, particularly those that result in loss of P14ARF function. We found that the p16 gene is one of the most commonly inactivated tumor suppressor genes detected thus far in primary NSCLC and that p16 alterations and p53 mutations are frequently found in the same tumor. Our results con®rm that the simultaneous abrogation of the P16/RB and TP53 pathways is important in lung cancer progression but provide little evidence for a functional equivalence between p14 ARF inactivation and p53 mutation in tumorigenesis.
Results

p16/p14
ARF analysis
Microsatellite markers¯anking the INK4A-ARF locus were used to map 38 NSCLCs at the 9p21 locus. Loss of heterozygosity (LOH) was detected in 28 of 38 (74%) of all tumors including 13 adenocarcinomas (AD) and 15 squamous cell carcinomas (SCC) ( Table  1) . Homozygous deletions were detected in seven (39%) AD and ®ve (25%) SCC. Previous work has demonstrated a correlation between homozygous deletions (detected with microsatellite markers) and FISH analysis in primary tumors (Cairns et al., 1995) . All the tumors exhibiting homozygous deletions by this analysis also revealed absence of P16 staining by IHC. Figure 1a shows the relative position of all the markers used in this study relative to the p16/p14 ARF locus. Most of the patients showed homozygous deletions spanning the D9S1748 and D9S2136 markers, indicating the loss of both p16 and P14
ARF genes (Figure 1b) . Interestingly, two tumors (number T21 and T8) exhibited apparent retention of marker D9S2136 but not D19S1748 suggesting that the homozygous deletion excludes exon 1b of the P14 ARF gene. Conversely samples T3, T20 and T22 showed apparent retention of D9S1748 (close to P14 ARF ) but not the D9S2136 (close to p16) marker. Although these ®ndings suggest the selective loss of p14 ARF , the absence of P16 protein staining (assessed by IHC) indicates that the p16 gene was also homozygously deleted.
One tumor (T8) was identi®ed as having morphologically distinct elements of neoplastic cells populations in the same tissue section by light microscopy. These two areas were separately microdissected and microsatellite analysis revealed LOH (deletion of a single copy of p16) in one of the neoplastic components and T1  T2  T3  T4  T5  T6  T7  T8  T9  T10  T11  T12  T13  T14  T15  T16  T17  T18  T19  T20  T21  T22  T23  T24  T25  T26  T27  T28  T29  T30  T31  T32  T33  T34  T35  T36  T37  T38   SCC  SCC  SCC  SCC  SCC  AD  AD  AD  AD  SCC  SCC  SCC  SCC  SCC  AD  SCC  SCC  SCC  SCC  AD  AD  AD  AD  SCC  AD  SCC  AD  AD  AD  AD  SCC  AD  AD  AD  AD  SCC  SCC  AD (7) (7) (7) (7) (7) (7) (7) (7) (7)* (7) (7) (7) (7) (+) (+) (+) (+) (+) (+) (7) (7) (7) (7) (7)* (7) (7) (7) (7) (+) (+) (+) (+) (+) (7) 
*, slight signal, probably due to a low level of interaction between P16 antibody and P16 mutated protein. SCC, squamous cell carcinoma; AD, adenocarcinoma; HD, homozygous deletion; LOH, loss of heterozygosity; PM, promoter hypermethylation; NA, not analysed; Del., deletion; nt, nucleotide; (7), (+) negative or positive for P16 immunostaining; 7, negative for genetic or epigenetic alteration at any of the genes analysed Figure 2 ). Finally, p53 mutation analysis showed the same mutation in both components. We then proceeded with complete sequence analysis of all exons in the INK4A-ARF locus. No point mutations in exon 1b of the p14 ARF gene were detected. The only variation observed was a GGC to AGC change at codon 25. This was con®rmed to be a polymorphism after sequence analysis of the lymphocyte DNA. We found two mutations in exon 2 of the p16 gene, one in codon 116 and the other a 7 bp deletion between nucleotides 243 and 249 predicting a truncated protein (Figure 3a ). These alterations were not observed in the corresponding normal tissues of the patients excluding the possibility of a polymorphism. Both mutations had loss of heterozygosity in the remaining allele in agreement with Knudson's hypothesis. Interestingly, tumors with a p16 mutation and LOH in the remaining allele (tumors T24 and T9) showed a weak P16 protein signal by IHC.
We further analysed the p16 gene for inactivation by ®ve prime CpG methylation . Methylation of the p16 promoter was detected in eight out of 38 (21%) of the primary tumors. Figure 3b is an example of the methylation assay (MSP) showing methylated and non-methylated tumor DNA and controls. All tumors that exhibited promoter methylation displayed complete absence of P16 staining by IHC. Two additional samples (T34 and T35) had absence of the P16 protein without any apparent molecular inactivation of the gene (Table 1) . Small homozygous deletions probably account for this discrepancy. However, it is possible that another gene in the p16 pathway is inactivated in these tumors leading to down regulation of P16 expression, or, ARF and p53 gene inactivation in NSCLC M Sanchez-Cespedes et al alternatively, point mutations outside of the sequenced regions could account for this observation. Recently, ®ve prime UTR point mutations of the p16 gene were discovered in the germline of some melanoma families, and found to reduce P16 expression (Ling et al., 1999) .
After comprehensive analysis of this locus, we observed that 58% of these primary tumors had p16 inactivation by homozygous deletion, promoter hypermethylation or point mutation. The p14 ARF gene was inactivated by homozygous deletions that extended into the INK4A/ARF locus and possibly by the two mutations in the shared p16 ± p14 ARF exon 2. All of these genetic alterations were con®rmed by a lack of P16 staining on the primary tissue. It is possible that the assessment of p14 ARF abnormalities is an underestimate based on the fact that a small deletion including only exon 1b would be missed by our analysis. Moreover, hypermethylation of the ®ve prime regions of the p14 ARF gene could be present even though it appears to be very rare (Robertson and Jones, 1998) .
p53 mutation analysis
The status of the p53 tumor suppressor gene in these primary tumor samples was analysed by a combination of manual sequencing and the GeneChip Assay (Aymetrix, Santa Clara, CA, USA). Manual sequencing was done on exon 5 ± 9 and the Chip analysis includes exon 2 ± 11. We found that 18 of the 37 tumors analysed (47%) harbored a p53 mutation (Table 1) .
Relationship between p53 and p14
ARF
We then compared the presence of a p53 point mutation and p14 ARF inactivation in these primary tumors. As can be seen in Table 1 Interestingly, most of the samples with p53 inactivation showed the presence of concomitant p16 alterations. A simultaneous inactivation of P16/RB pathway and p53 mutations may indicate collaboration between the two pathways and may represent an advantage for tumor progression.
Discussion
Several threads of evidence have converged to elucidate the role of p14ARF in the cell cycle. It is now known that P14ARF can bind to human MDM2 resulting in the increase of wild type TP53 protein. An increase in the expression of P14ARF leads to an increase in TP53 activity including upregulation of p21 and cell cycle arrest (Chin et al., 1998) . Moreover, P14
ARF knockout in the mouse leads to the occurrence of tumors with a similar spectrum to that seen in mice that lack the p53 gene (Kamijo et al., 1997) . Based on these exciting observations, it was hypothesized that p14 ARF inactivation and p53 mutations in human cancers should be mutually exclusive since they would both act on the same TP53 pathway (Chin et al., 1998) . However, we did not ®nd an inverse correlation between p14 ARF genetic alterations and p53 point mutations in primary lung cancers. These results are supported by a previous report using less de®nitive immunohistochemical techniques also suggesting a lack of correlation between p14 ARF inactivation and p53 (Gazzeri et al., 1998) . Our report is based on comprehensive genetic analysis of the p14 ARF gene and this type of approach has been performed previously in only a small subset of human cancers (Stone et al., 1995; Gazzeri et al., 1998) . A more recent report also found the common occurrence of p53 and p14 ARF inactivation in a subset of bladder cancers (Markl and Jones, 1998). However, the authors attributed this lack of correlation to the restriction of p53 mutations within exons 2 ± 4. Our data in a much large number of primary tumors does not support this observation in lung cancer since we found p14 ARF alterations occurring with mutations in all the known exons that are commonly mutated in p53.
As reviewed previously (Sidransky 1996; Chin et al., 1998) , the evidence for a direct role of p14 ARF alterations in human cancer through genetic analysis has been lacking. Only a few exon 1b deletions (exclusive p14 ARF deletions that did not include the p16 coding sequences) have been found in rare cell lines (Larsen, 1996) . As in our study, virtually all exon 1b deletions also extend into the p16 locus and result in complete inactivation of p16. The absence of exclusive p14 ARF genetic alterations and the lack of inverse correlation between p14 ARF and p53 genetic changes are not consistent with an equivalent loss of function for p14 ARF in the same p53 biochemical pathway. However, the simultaneous presence of p14 ARF and p53 gene alterations is not conclusive because the timing of the mutation events may also be critical. It is possible that p53 abnormalities occurs ®rst in some NSCLC and then the subsequent loss of p14 ARF by homozygous deletions may be incidental to the loss of p16.
A recent report in neoplastic keratinocyte cultures found a critical role for p16 but not p14 ARF in senescence. The p16 inactivation was invariably associated with an immortal phenotype and detailed analysis provided evidence of p16 deletion independent of p14 ARF loss (Munro et al., 1999) . In the P16/RB pathway an inverse correlation between p16 and Rb inactivation is common. In lung cancer, p16 and Rb mutations are almost always mutually exclusive (Kratzke et al., 1996; Kinoshita et al., 1996) . However, a few tumors have been described with p16 and Rb alterations suggesting that either one of these genetic changes may lead to an additional growth advantage for the transformed cell. In this regard, it is possible that p53 mutations confer an additional advantage to loss of p14 ARF in primary tumors. Because the p53 gene has a myriad of functions involved in tumor suppression and even the potential for an oncogenic function of p53 mutation, p53 mutations may target additional events for further clonal selection.
Previous data have found an association between p53 mutations and RB loss of expression in several tumor types (e.g. bladder cancer) (Markl and Jones, 1998) . These ®ndings are in agreement with the observation that Rb +/7 p53 7/7 mice show a broader spectrum of tumors than those mice either Rb +/7 or p53 7/7 alone (Ko and Prives, 1996). Although we did not analyse for Rb inactivation, it is clear that simultaneous inactivation of TP53 and RB biochemical pathways may represent an advantage for tumor development. It is also interesting that one third of these primary tumors did not inactivate any component of the p53 pathway. It can be speculated that other as yet undiscovered alterations such as MDM2 ampli®cation or other genes in the p53 pathway may be altered in primary lung cancer.
Finally, on one invasive tumor we have shown in vivo neoplastic progression through p16 inactivation. Although the loss of 9p21 occurs early and frequently in non-small cell lung cancer, it appears that complete p16 inactivation occurred later in the progression of this cancer. Additional tumor suppressor genes are likely to contribute to the neoplastic progression of non-small cell lung cancer, however, it is clear that both P16/RB and TP53 pathways are commonly inactivated in most primary lung cancers.
Materials and methods
Primary tumor samples and DNA extraction
Thirty-eight randomly selected primary fresh frozen tumor specimens were obtained from the Johns Hopkins Hospital Department of Surgical Pathology Tumor Bank for use in this study following surgical resection with prior consent from Johns Hopkins Hospital patients. These specimens were then microdissected on a cryostat to select for greater than 70% neoplastic cells prior to DNA extraction. Blood was obtained from each patient and lymphocyte DNA was isolated as described for use as a normal control .
Immunohistochemistry
Fresh frozen specimens were embedded in Optimum Cold Temperature Medium (OCT, Tissue-Tek, Miles, Elkhart, NI, USA), sectioned and mounted on lysine coated slides as previously described (Reed et al., 1996) . These slides were examined by a pathologist (WH Westra) prior to microdissection or immunohistochemistry).
Immunohistochemistry (IHC) was performed as previously described with the use of a P16 monoclonal antibody, DCS-50, which preferentially recognizes denaturalization-resistant epitopes on the carboxyl-terminus of p16 protein (Reed et al., 1996) . Brie¯y, 5 mm thick frozen tumor sections were ®xed on lysine coated slides in a 1 : 1 cold acetone/methanol solution. After blocking sera was applied for 15 min, sections were reacted with primary p16 mAb in a 1 : 500 dilution overnight at 48C. Immunolocalization was performed with the use of Vectastain Elite ABC Kit (Vector Laboratory, Burlingame, CA, USA), 3,3'-diaminobenzidine tetrahydrochloride (DAB) (Vector Laboratory, Burlingame, CA, USA) chromagen and nickel enhancement was used to localize P16 mAb binding in tissue sections. After DAB development, tissues were counterstained using Gill's hematoxylin and mounted in an aqueous medium. The slides were evaluated using standard light microscopy by two observers (WH Westra and A Reed). A squamous cell carcinoma of the larynx cell line (JHU-020-SCC-L) with a homozygous deletion of p16 was used as a negative control. H82, a Rb 7/7 small cell lung cancer cell line was used as a positive control. For nonspeci®c staining, normal preimmune mouse serum (Vector Laboratory, Burlingame, CA, USA) was used as a background control. Only nuclear staining was regarded as positive staining. In¯ammatory cells and reactive stromal cells served as positive internal controls.
Allelic loss
Seven polymorphic microsatellite markers at the p16 locus on chromosome 9p21 were ampli®ed by the Polymerase Chain reaction (PCR) to detect dinucleotide repeat polymorphisms in primary HNSCC tumor DNA and corresponding blood lymphocyte DNA as previously described (Reed et al., 1996) . Criteria for the detection of loss of heterozygosity (LOH) and homozygous deletions have been previously described (Cairns et al., 1995) . Determination of homozygous deletion was based on the presence of one or more closely spaced microsatellite markers demonstrating apparent`retention' when¯anked by markers showing clear LOH. This apparent retention is due to low level ampli®cation of normal alleles from small amounts of non-neoplastic cells within the primary tumor without any contribution of the homozygously deleted region from the neoplastic cells (Cairns et al., 1995) . Primer sequences can be obtained from Research Genetics (Huntsville, AL, USA) or from the Genome Database (www.gdb.org) (D9S157, INFa, D9S2136, D9S1748, D9S1749, D9S171, D9S126). 
5' CpG promoter methylation
Fifty nanograms of DNA mixed with 1 mg of salmon sperm DNA as a carrier was treated with hydroquinone and sodium bisulfate at 508C for 16 h. Modi®ed DNA was puri®ed using the Wizard DNA puri®cation resin (Promega). Sodium hydroxide was added to complete the modi®cation followed by ethanol precipitation. Resuspended DNA was used in a PCR reaction containing 16PCR buer, 1.25 mM dNTP's, 300 ng of each primer, and 50 ng of bisulfate-modi®ed DNA. The methylated (M) p16 template was ampli®ed with primers: 5'-TTATTAGAGGGTGGGGCGGATCGG and 5'-GACC-CCGAACCGCGACCGTAA and the unmethylated (U) template with the primers: 5'-TTATTGAGGGGTGGG-GTCGGATTGT and 5'-CAACCCCAAACCACAACCA-TAA. PCR conditions included hot start PCR at 958C for 5 min, before addition of 1.25 units of Taq polymerase (BRL) and 35 cycles at 958C for 30 s, 658C for 30 s (methylated) or 608C (unmethylated), and 728C for 30 s, followed by a 4 min extension at 728C. Each PCR was run on a non-denaturing 6 ± 8% polyacrylamide gel and stained with ethidium bromide. Data analysis was by visual interpretation based on the exquisite speci®city of each primer pair for the respective templates. The U primers amplify only sodium bisulfate-treated unmethylated DNA producing a PCR product of 154 bp and the M primers amplify only sodium bisulfate-treated methylated DNA producing a PCR product of 145 bp as previously described (Herman et al., 1996) .
DNA sequencing by the GeneChip p53 assay
Half of the tumors were manually sequenced (from exon 5 to exon 9) as previously described (Sidransky et al., 1991) . The remaining samples were sequenced using the GeneChip 1 p53 assay, per the manufacturer's protocol (Aymetrix, Santa Clara, CA, USA). Exons 2 through 11 of the p53 gene for each tumor and the normal reference DNA were ampli®ed as 100 separate amplicons in a single PCR reaction. Each reaction contained 250 ng of genomic DNA, 5 ml of the p53 primer set (Aymetrix), 10 U AmpliTaq Gold (Perkin Elmer), PCR buer II (Perkin Elmer), 2.5 mM MgC1 2 and 0.2 mM of each dNTP in a ®nal volume of 100 ml. The reaction tubes were then heated to 958C for 10 min followed by 35 cycles of 958C for 30 s, 608C for 30 s and 728C for 45 s followed by a ®nal extension of 10 min at 728C. Forty-®ve microlitres of ampli®ed tumor and reference DNA were then fragmented with 0.25 U fragmentation reagent (Aymetrix) at 258C for 18 min in 2.5 U calf intestine alkaline phosphatase, 0.4 mM EDTA and 0.5 mM Tris-acetate (pH 8.2) followed by heat inactivation at 958C for 10 min. The fragmented amplicons were 3'-end labeled with fluoresceinated dideoxy AMP. Fifty microliters of fragmented DNA were incubated at 378C for 45 min in a 100 ml reaction containing 25 U terminal transferase (Boehringer Mannheim). TdTase buer, 10 mM¯uorescein-N6-ddATP followed by heat inactivation at 958C for 5 min. Thē uorescein-labeled sample was then hybridized in a 0.5 ml reaction containing 66SSPE, 0.05% Triton X-100, 1 mg acetylated BSA, and 2 nM control oligonucleotide F1 (Aymetrix) to the p53 probe array for 30 min at 458C. The probe array was washed four times with wash buer A and then scanned by laser (HP GeneArray Scanner, Hewlett Packard Co.). Intensity patterns diering from the reference sample are quanti®ed, and sites containing mutant bases are then displayed by the GeneChip software with an assigned score (range 0 through 32) corresponding to the dierence in intensity. Scores exceeding an empirically determined threshold of 13 were then identi®ed as mutations. A direct comparison between standard sequence analysis and the gene chip array system has demonstrated excellent reproducibility between the two approaches and has been submitted elsewhere (Arhendt et al., in press ).
Sequence analysis for p16 and p14
ARF
One hundred nanograms were used to individually amplify exons 1 and 2 of the p16 gene and exon 1b for the p14 ARF gene by PCR. Primers and PCR conditions were described previously (Cairns et al., 1994; Mao et al., 1995) . PCR products were used as templates for cycle sequencing. Sequencing primers were labeled by g-32 P-ATP and subjected to PCR ampli®cation using the AmpliCycle sequencing kit (Perkin Elmer, Roche Molecular Systems Inc., Brachburg, NJ, USA) according to the manufacturer's protocol. Sequenced products were separated electrophoretically through 6% polyacrylamide gels, dried and ®nally exposed to ®lm for 24 ± 48 h. Abbreviations AD, adenocarcinoma; HD, homozygous deletion; IHC, immunohistochemistry; LOH, loss of heterozygosity; NSCLC, non small cell lung cancer; SCC, squamous cell carcinoma
